Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn's disease, Rheumatoid Arthritis and lupus disease. Neovacs SA's portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
- TickerA1CVKR
- ISINFR0004032746
- ExchangeFrankfurt Stock Exchange
- SectorPharmaceuticals & Biotechnology
- CountryFrance
Access reports individually or via Subscription
Receive monthly invoices with payment via CSA or hard dollars
Analyst access
Free Trial Subscriptions
Team account with shared subscriptions
Advanced analytics to track research consumption and performance
